The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Belantamab mafodotin, bortezomib, and dexamethasone (BVd) treatment showed “significant benefit” in progression-free survival (PFS) when compared with daratumumab, bortezomib, and dexamethasone (DVd) in
In this video interview from the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO), Bijal Shah, MD, of the Moffitt Cancer
The US Food and Drug Administration (FDA) has approved epcoritamab-bysp (EPKINLY) for the treatment of adults with relapsed or refractory follicular lymphoma after
The US Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for
https://youtu.be/xP3dZWHtfKs In this video filmed at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024), Hagop Kantarjian,MD, professor and chair
https://youtu.be/RBEA0etwdyA Hagop Kantarjian, MD, professor and chair in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, sat down
The addition of the bispecific T-cell engager blinatumomab to consolidation chemotherapy in adults patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) who had
For the first time in history, the Society of Hematologic Oncology (SOHO) is holding a joint session with the Brazilian Association of Hematology,
